Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team

Vancouver, British Columbia – (September 19th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team.

 

Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory team. His achievements in scientific and clinical research space will be a major asset to BioMark.  Dr. Tappia’s expertise in regulatory and clinical research brings depth and practicality as we begin to commercialize and position our technology for different oncology applications and potential linkages with other leading global institutions.”

 

“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment for cancers at large. BioMark’s technology platform could be a critically important tool for clinicians and the medical institutions”, says Dr. Tappia.

 

About Dr. Paramjit Tappia

Dr. Tappia over 30 years of research, including clinical and regulatory experience in clinical research with focus on nutrition in health and disease, developing novel biomarkers for human disease and understanding of subcellular and molecular mechanisms of different pathophysiological conditions. He is currently the Principal Investigator and Clinical Scientist at Asper Clinical Research Institute, St. Boniface Hospital where he manages and facilitates clinical studies for major corporations. Dr. Tappia holds Ph.D. in Biochemistry from University of Wolverhampton, U.K. and has published over 100 peer-reviewed articles in leading journals and 26 book chapter contributions. Dr. Tappia is regularly invited to present at national and international conferences. He is also actively involved in various community services across the province of Manitoba.

Press Release – Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team

BioMark Partners with Alberta Machine Intelligence Institute to Amplify Clinical Diagnostic Decision Making

Vancouver, British Columbia – (April 25, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to announce that it has penned a deal with the Alberta Machine Intelligence Institute (Amii) led by Dr. Osmar Zaïane of the University of Alberta’s Department of Computing Science and his team to assess and employ machine intelligence to augment BioMark’s breakthrough biological molecular diagnostics for lung cancer that leverages the power of metabolomics.

BioMark, over the past few months, has been actively working with the team at Amii to find optimal methodologies to increase the prediction and accuracy of its assays. President and CEO Rashid Bux says, “We realize the importance of machine and deep learning in the future of healthcare delivery. There is immense impact in patient care outcome and faster diagnostic utility for clinicians through incorporating machine intelligence capabilities. Our initial objective is to increase the performance and prediction of our lung cancer diagnostic assays by reducing data bias to establish consistency. Eventually, we aim to establish models that have the ability to predict trends in our network, which will amplify decision making for clinicians. Once completed, BioMark intends to incorporate this as an application-driven breakthrough embedded seamlessly onto our technology platform. BioMark is delighted to work with Dr. Zaïane and Amii from University of Alberta who are creating game changing applications using machine learning and artificial intelligence.”

 

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

 

About Alberta Machine Intelligence Institute (Amii)

The Alberta Machine Intelligence Institute (Amii) is a world-leading research group at the University of Alberta in Edmonton specializing in machine intelligence. One of three hubs in Canada’s Pan-Canadian AI Strategy, Amii conducts advanced research and development in the many subfields of machine learning and artificial intelligence. Amii researchers collaborate with a variety of organizations to help push the bounds of scientific knowledge and develop innovative, adaptive solutions for businesses in Alberta and beyond. Learn more at www.amii.ca

Press Release – BioMark Partners with Alberta Machine Intelligence Institute to Amplify Clinical Diagnostic Decision Making

BioMark Diagnostics – Sponsored Project Receives NSERC Engage Grant

Vancouver, British Columbia – (February 27th, 2018)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with Donald Miller, Ph.D., Professor, Department of  Pharmacology and Therapeutics  at the University of Manitoba, to fabricate new nanomaterial and focus on evaluation of these new nanomaterial for knocking down SSAT1 expression in various cells .The up regulation of  SSAT enzyme  has been clinically demonstrated by BioMark and others to be highly elevated in  lung, breast, prostate and brain cancers.

President and CEO, Rashid Ahmed explains, “We are delighted to be working with Dr. Miller and his team at the University of Manitoba to help BioMark assess the potential of designing new nanomaterials that can be used to target the metabolic pathway associated in the up-regulation of SSAT for various cancers.   Dr. Miller has domain expertise and over 20 years of experience in fabricating, evaluating and developing polymer and metal oxide based nanoparticle compounds and delivery systems for various applications including the brain. He will direct the project and supervise the design of these novel nanomaterial candidates which provide more options to deliver a knock down SSAT compound enabling a potential better treatment associated with various cancers.”

Rashid says, “BioMark is grateful to the Canadian government for awarding it yet another grant that supports work to advance this important technology toward commercialization.”

Press Release – BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant

BioMark’s Health Canada Submission Update

Vancouver, British Columbia – (February 21st, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical trial activities.

Listed below are new accomplishments over the past 2 weeks:

  1.  BioMark’s regulatory team at St. Boniface Hospital Research Centre and the assigned biostatistician have completed detailed data analysis and tabulation on clinical trials based in Canada and Bangladesh.
  2. A comprehensive medical follow up report of the outliers in both in Canada and Bangladesh has been reviewed by Dr. Andrew Maksymiuk, the Principal Investigator at CancerCare Manitoba along with our regulatory team members from St. Boniface Hospital Research Centre. Initial assessment report of the outliers demonstrates BioMark SSAT1 technology can provide physicians an economical diagnostic tool to effectively pre-screen patients for either more expensive CT screening or more invasive biopsy procedure. (Outliers are subjects who were considered healthy but exhibited higher than expected Acetyl Amantadine concentrations). An ongoing follow up will serve as part of our surveillance and strengthen the clinical applicability of our data.
  3. Compilation of the package to be filed with Health Canada has begun and a team has been assembled to accelerate the submission.

Next Steps
News will be released as soon as the submission package is completed in the next couple of weeks.

News Release – BIOMARK’s Health Canada Submission Update